RPG Life Sciences Q3FY26 Results: Profit Before Tax at ₹291 Crore, API Division Transfer in Progress
RPG Life Sciences reported Q3FY26 standalone and consolidated Profit Before Tax of ₹2.91 crore. The company is transferring its API division to a subsidiary, RPG Active Pharma Limited, expected to conclude by February 2026. Exceptional expenses include ₹8.42 crore for Q3FY26, comprising a net fire incident loss and ₹11.08 crore impact from New Labour Codes.
The announcement clarifies financial reporting and provides updates on a significant corporate restructuring (API division transfer). The impact of new labor codes and the fire incident, though explained, represent material items that could affect future profitability and operations. The clarification itself is important for regulatory compliance.
The announcement is primarily a response to an exchange clarification regarding financial results. While it provides financial figures and details on a corporate restructuring, there are no significant positive or negative surprises. The exceptional items, particularly the impact of new labor codes and the fire incident, introduce a degree of caution.
RPG Life Sciences Limited has submitted its financial results for the quarter and nine months ended December 31, 2025, addressing clarifications sought by the National Stock Exchange of India Limited. The company confirmed that the financial results were submitted in a legible and machine-readable format, as verified by NSE officials.
Regarding the financial performance, for the quarter ended December 31, 2025, the company reported a Profit Before Tax of ₹2,912 lakhs (₹2.91 crore) on a standalone basis and ₹2,912 lakhs (₹2.91 crore) on a consolidated basis. For the nine months ended December 31, 2025, the standalone Profit Before Tax was ₹11,120 lakhs (₹111.20 crore) and consolidated Profit Before Tax was ₹11,400 lakhs (₹114.00 crore).
A significant corporate development is the approval by the Board of Directors on December 15, 2025, to transfer the API division to its wholly-owned subsidiary, RPG Active Pharma Limited. This transfer is aimed at streamlining the business structure and improving operational focus. The subsidiary was incorporated on December 24, 2025, and commenced business on January 6, 2026. The transaction is expected to be concluded by February 2026, subject to requisite approvals and customary conditions precedent. Due to this internal reorganization, the standalone and consolidated financial results for the quarter ended December 31, 2025, show the same figures.
The company also provided details on exceptional items. For the quarter ended December 31, 2025, there was an exceptional expense of ₹842 lakhs (₹8.42 crore) on a standalone and consolidated basis. This includes a net loss of ₹245 lakhs related to a fire incident at the API plant in Navi Mumbai, for which the company is confident of recovering the loss from the insurance company. Additionally, an incremental obligation of ₹1,108 lakhs (₹11.08 crore) was recognized due to the impact of the New Labour Codes, which came into effect on November 21, 2025. The company is reassessing and implementing policy changes related to employee benefits in light of these new codes.
The financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors on January 27, 2026. The company operates in a single reportable business segment: Pharmaceuticals.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.